64 results
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
25 Apr 24
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024
8:03am
and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
16 Apr 24
Virax Biolabs Group Limited to Participate at ESCMID Global 2024
7:34am
prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
15 Mar 24
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
4:32pm
statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates
6-K
EX-10.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Current report (foreign)
5:28pm
is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature … the Company on related or other matters). The Company agrees that it will not claim that the Manager has rendered advisory services of any nature
424B5
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Prospectus supplement for primary offering
5:27pm
these identifying words.
The statements we make regarding the following matters are forward-looking by their nature and are based on certain
6-K
EX-99.1
sw0n6zz1
21 Dec 23
Current report (foreign)
7:34am
6-K
EX-99.1
ip7bkdmvuqc70vmbo
20 Dec 23
Current report (foreign)
4:06pm
6-K
EX-99.1
r1bdfb9iori9
18 Dec 23
Virax Biolabs’ CEO James Foster Issues Letter to Shareholders
7:37am
6-K
EX-99.1
z306eq khjch068x
14 Dec 23
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation
7:43am
6-K
EX-99.4
4g1jf qk8pw95b0ha0p
8 Nov 23
Current report (foreign)
4:11pm
6-K
EX-99.3
0bnaxy e8
8 Nov 23
Current report (foreign)
4:11pm
D
1r6t0cz
17 Oct 23
$2.15 mm in equity / options / securities to be acquired, sold $2.15 mm, 1 investor
4:05pm
6-K
EX-99.1
xqds6 xv0lxz52k5n1
12 Sep 23
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar
7:49am
6-K
EX-99.1
gutuc3xeb3eybc8oivxv
1 Sep 23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
7:37am
6-K
EX-99.1
287j42mj06h6g1elq2ml
3 Aug 23
Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid
8:39am
6-K
EX-99.1
gy01vksv d4eo1
18 Jul 23
Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities
7:58am
6-K
EX-99.1
mj8ga qoqj59c1zjf
14 Jun 23
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
8:00am